Hong Kong to Resume BioNTech Shots Monday After Defect Scare

Hong Kong to Resume BioNTech Shots Monday After Defect Scare
Bloomberg
4/1/2021
Jinshan Hong and Chloe Lo
© Bloomberg
A staff member assists a person outside a closed community vaccination center administering the BioNTech Covid-19 vaccine imported by Fosun Pharma in Hong Kong, China, on Wednesday, March 24, 2021. Hong Kong and Macau temporarily suspended Covid vaccines manufactured by BioNTech SE because of a packaging defect, dealing a blow to the cities' efforts to revive their pandemic-battered economies.
(Bloomberg) -- Hong Kong will resume administering BioNTech SE Covid shots on Monday after authorities concluded that the recent emergence of defective vials didn’t pose a safety risk, capping a 12-day halt that’s further damaged confidence in the city’s dismal vaccine rollout.

Related Keywords

Germany ,China ,Beijing ,Taiwan ,Hong Kong ,Macau ,Singapore ,Chinese ,German ,Bloomberg Hong Kong ,Biontech Covid ,Fosun Pharma ,Health Constance Chan ,Pfizer Inc ,Civil Service Patrick Nip ,Sinovac Biotech Ltd ,Shanghai Fosun Pharmaceutical Group Co ,Health Sophia Chan ,Sinovac Biotech ,Fosun Pharmaceutical Group ,ஜெர்மனி ,சீனா ,பெய்ஜிங் ,டைவாந் ,ஹாங் காங் ,மக்காவு ,சிங்கப்பூர் ,சீன ,ஜெர்மன் ,ப்ளூம்பெர்க் ஹாங் காங் ,ஆரோக்கியம் நிலைத்தன்மை சான் ,ஃபைசர் இன்க் ,சிவில் சேவை பேட்ரிக் நீப் ,ஆரோக்கியம் சோபியா சான் ,